At a glance
ClinicalIndex Comparison Record- ✓Age 18–50 years
- ✓BMI 18.5 to <25 kg/m²
- ✕Significant use of systemically-absorbed glucocorticoids currently or within the prior 6 months
- ✕Current use of antihypertensive medications
- ✕Current use of metformin or any antidiabetic medications
- ✕Current use of medications that affect dexamethasone metabolism (phenytoin, rifampin, carbamazepine, troglitazone, barbiturates)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Diagnosing Natriuretic Peptide Deficiency: A Pilot Study
In Brief
A Phase 1 clinical trial evaluating Dexamethasone for Healthy and Lean. Completed, enrolled 10 participants across 1 site.
Detailed Summary
In this pilot study, the investigators will determine the response of the natriuretic peptide (NP) hormone system after a dose of intravenous dexamethasone (a steroid medication). The goal of the proposed project is to generate preliminary data that will be used to develop power calculations, inform cutoff ranges, and inform the timing of the NP response for larger subsequent studies. Aim: To determine the range of distribution and time course of natriuretic peptide (NP) responses to a single dose of dexamethasone IV 4 mg in healthy lean individuals. Hypothesis: Determination of the NP responses (the range and time course of changes in NP levels) to dexamethasone in 10 healthy individuals will inform the time course and frequency of blood sampling in a definitive prospective study, as well as enable investigators to perform a sample size calculation for a definitive prospective study.
Study Details
Timeline
Interventions
A single dose of dexamethasone IV 4 mg will be administered.